OraSure Technologies Supports Rapid HIV Testing Initiatives for World AIDS Day
01 Dicembre 2010 - 12:00PM
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral
fluid diagnostics, today announced its support of more than 150
rapid HIV testing initiatives taking place in more than 25 states
in the U.S. and numerous countries globally, in recognition of
World AIDS Day, commemorated annually on December 1st. OraSure's
support of these initiatives, taking place in Africa, Asia, Europe,
North and South America, is focused on promoting increased HIV
prevention and testing with the use of the Company's OraQuick®
ADVANCE Rapid HIV-1/2 Antibody test kits.
OraSure will also preside over the NASDAQ Market Open Ceremony
on December 1st in observance of World AIDS Day and will be joined
at this ceremony by New York State Assemblyman Darryl C. Towns and
State Senator Tom Duane. The state legislators are expected to
issue a proclamation on behalf of the State of New York honoring
the late Dennis deLeon, the founder and former executive director
of the Latino Commission on AIDS, and one of the primary champions
of the recent New York State HIV testing law (S8227 and A.11487),
which encourages routine HIV testing for all people aged 13 to
64.
Now in its 23rd year, World AIDS Day is an international day of
observance to honor those who have died from AIDS and increase
awareness of the disease in hopes of fighting the spread of HIV.
According to UNAIDS, 33.3 million people worldwide were living with
HIV in 2009. Worldwide, most people living with HIV are unaware
that they are infected.
"We are proud to be part of such an important day that brings
together people all over the world in the fight against HIV/AIDS,
and hope that our work at OraSure to advance testing for infectious
diseases like HIV, will help reverse the devastating impact that
this disease has had around the world," said Douglas A. Michels,
President and CEO of OraSure Technologies. "On this day we also
pause to honor a great leader and friend to all in the HIV
community, Dennis deLeon, who passed away nearly a year ago, and
leaves a legacy of national service and advocacy on behalf of those
affected by HIV and AIDS."
Committed to working with local, national and international
agencies to fight HIV/AIDS, OraSure is actively supporting testing
and education campaigns around the world that urge people to learn
their HIV status.
The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, manufactured
and sold by OraSure Technologies, is the first and only U.S. Food
and Drug Administration ("FDA") approved and CLIA waived rapid
point-of-care test that can detect antibodies to both HIV-1 and
HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture
whole blood and plasma specimens. The OraQuick® test is used by
hospitals, state departments of health, clinics, community-based
organizations, and college/university health centers throughout the
country and around the world.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral
fluid specimen collection devices using proprietary oral fluid
technologies, diagnostic products including immunoassays and other
in vitro diagnostic tests, and other medical devices. These
products are sold in the United States as well as internationally
to various clinical laboratories, hospitals, clinics,
community-based organizations and other public health
organizations, distributors, government agencies, physicians'
offices, and commercial and industrial entities. For more
information on the Company, please go to www.orasure.com.
The OraSure Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6440
CONTACT: OraSure Technologies, Inc.
Investor Contact:
Ronald H. Spair, Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
Zer0 to 5ive for OraSure Technologies
Media Contact:
Jennifer Moritz
917-748-4006
jmoritz@0to5.com
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024